Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

10/24/2025

Janusmed kön och genus

Janusmed kön och genus – Primperan injectie 10/2 ml

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Metoklopramid Testmiljö

Metoklopramid

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Fass R, Pieniaszek HJ, Thompson JR. Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Aliment Pharmacol Ther. 2009;30:301-6.

  2. Primperan (metoklopramid). Summary of Product Characteristics. Medical Products Agency; 2014.

  3. Roila F, Tonato M, Basurto C, Canaletti R, Morsia D, Passalacqua R et al. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep. 1985;69:1353-7.

  4. Tsavaris N, Mylonakis N, Bacoyiannis C, Kosmas C, Kalergis G, Iakovidis V et al. Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy. Oncol Rep. 1998;5:1147-55.

  5. Kreel L, Trott M, Howells TH. The influence of oral metoclopramide on gastric emptying after a fixed water load. Clin Radiol. 1972;23:213-8.

  6. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985;291:930-2.

  7. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3:138-48.

  8. Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013;13:152.

  9. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18:701-15.

  10. Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46:494-503.

  11. Kauppila A, Kivinen S, Ylikorkala O. A dose response relation between improved lactation and metoclopramide. Lancet 1981;1(8231):1175-1177.

  12. Ylikorkala O, Kauppila A. The effects on the ovulatory cycle of metoclopramide-induced increased prolactin levels during follicular development. Fertil Steril. 1981;35:588-9.

  13. Kauppila A, Leinonen P, Vihko R, Ylöstalo P. Metoclopramide-induced hyperprolactinemia impairs ovarian follicle maturation and corpus luteum function in women. J Clin Endocrinol Metab. 1982;54:955-60.

  14. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]

  1. Fass R, Pieniaszek HJ, Thompson JR. Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Aliment Pharmacol Ther. 2009;30:301-6.
  2. Primperan (metoklopramid). Summary of Product Characteristics. Medical Products Agency; 2014.
  3. Roila F, Tonato M, Basurto C, Canaletti R, Morsia D, Passalacqua R et al. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep. 1985;69:1353-7.
  4. Tsavaris N, Mylonakis N, Bacoyiannis C, Kosmas C, Kalergis G, Iakovidis V et al. Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy. Oncol Rep. 1998;5:1147-55.
  5. Kreel L, Trott M, Howells TH. The influence of oral metoclopramide on gastric emptying after a fixed water load. Clin Radiol. 1972;23:213-8.
  6. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985;291:930-2.
  7. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3:138-48.
  8. Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013;13:152.
  9. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18:701-15.
  10. Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46:494-503.
  11. Kauppila A, Kivinen S, Ylikorkala O. A dose response relation between improved lactation and metoclopramide. Lancet 1981;1(8231):1175-1177.
  12. Ylikorkala O, Kauppila A. The effects on the ovulatory cycle of metoclopramide-induced increased prolactin levels during follicular development. Fertil Steril. 1981;35:588-9.
  13. Kauppila A, Leinonen P, Vihko R, Ylöstalo P. Metoclopramide-induced hyperprolactinemia impairs ovarian follicle maturation and corpus luteum function in women. J Clin Endocrinol Metab. 1982;54:955-60.
  14. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]